Literature DB >> 25761402

Information of prostate biopsy positive core: does it affect MR detection of prostate cancer on using 3T-MRI?

Rika Yoshida1, Yasushi Kaji, Yukihisa Tamaki, Takashi Katsube, Hajime Kitagaki, Tsunehito Kanbara, Takao Kamai.   

Abstract

OBJECTIVE: We assessed which information from a prostate biopsy had the strongest relationship with prostate cancer detection by 3T-MRI.
MATERIALS AND METHODS: Sixty-one consecutive patients with biopsy-proven prostate cancer who underwent 3T-MRI before biopsy were enrolled in this retrospective study. Two radiologists independently reviewed T2-weighted and diffusion-weighted images. When the cancer lesions were revealed by biopsy and MRI depicted them at corresponding sites, we classified these lesions as MRI-detectable cancer. If the cancer lesions were revealed by biopsy, but any cancers had not been detected, we classified these lesions as MRI-undetectable cancer. We compared the Gleason score (GS), cancer ratio (CaR) and cancer length (CaL) from core biopsies between the two groups. THE
RESULTS: GS, CaR and CaL differed significantly between the MRI-detectable group (N = 70), and the MRI-undetectable group (N = 73). 3T-MRI could detect cancer cores with a sensitivity of 90.5% in cores with CaR ≥ 60%, and with a sensitivity of 81.8% in those with CaL ≥ 5 mm. Receiver operating characteristic analysis showed that CaR (P = 0.006) and CaL (P = 0.010) significantly associated with the prostate cancer detection using MRI rather than GS.
CONCLUSION: CaR and CaL from the core biopsies showed a stronger relationship to detection of the prostate cancer on 3T-MRI than the GS did.

Entities:  

Mesh:

Year:  2015        PMID: 25761402     DOI: 10.1007/s11604-015-0407-4

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  21 in total

1.  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.

Authors:  M C Roethke; T H Kuru; S Schultze; D Tichy; A Kopp-Schneider; M Fenchel; H-P Schlemmer; B A Hadaschik
Journal:  Eur Radiol       Date:  2013-10-03       Impact factor: 5.315

2.  Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.

Authors:  Hebert Alberto Vargas; Oguz Akin; Amita Shukla-Dave; Jingbo Zhang; Kristen L Zakian; Junting Zheng; Kent Kanao; Debra A Goldman; Chaya S Moskowitz; Victor E Reuter; James A Eastham; Peter T Scardino; Hedvig Hricak
Journal:  Radiology       Date:  2012-09-05       Impact factor: 11.105

3.  Definitive radiotherapy in resectable (stage A2 and B) carcinoma of the prostate--results of a nationwide overview.

Authors:  M V Pilepich; M A Bagshaw; S O Asbell; G E Hanks; J M Krall; B N Emami; R H Bard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-05       Impact factor: 7.038

4.  Percent of cancer in the biopsy set predicts pathological findings after prostatectomy.

Authors:  David J Grossklaus; Christopher S Coffey; Scott B Shappell; Gregory S Jack; Sam S Chang; Michael S Cookson
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

5.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.

Authors:  Courtney A Woodfield; Glenn A Tung; David J Grand; John A Pezzullo; Jason T Machan; Joseph F Renzulli
Journal:  AJR Am J Roentgenol       Date:  2010-04       Impact factor: 3.959

6.  Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.

Authors:  Hebert Alberto Vargas; Oguz Akin; Tobias Franiel; Yousef Mazaheri; Junting Zheng; Chaya Moskowitz; Kazuma Udo; James Eastham; Hedvig Hricak
Journal:  Radiology       Date:  2011-03-24       Impact factor: 11.105

7.  Prostate cancer, version 2.2014.

Authors:  James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

8.  Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy.

Authors:  W J Catalona; J W Basler
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

Review 9.  Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

Authors:  Kazuto Ito
Journal:  Int J Urol       Date:  2009-04-01       Impact factor: 3.369

10.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.

Authors:  K Wallner; J Roy; L Harrison
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.